Dr. Jordan Named to Chair in Memory of Princess Diana
January 1st 2000CHICAGO-V. Craig Jordan, PhD, has been named Diana, Princess of Wales, Professor of Cancer Research at Northwestern University. Dr. Jordan, a native of the United Kingdom, is professor of cancer pharmacology at Northwestern University Medical School and director of the Lynn Sage Breast Cancer Research program affiliated with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
First Phase II Results of Cisplatin/Epinephrine in Primary Liver Cancer
January 1st 2000The interim results of an ongoing phase II trial of IntraDose (cisplatin [Platinol]/epinephrine) were presented at the 17th Annual Chemotherapy Foundation Symposium in New York City. Of 29 evaluable patients with liver cancer, 12 (41%) responded to treatment. Of the 12 responders, 6 achieved a complete response (100% reduction in viable tumor volume), while the other 6 showed a more than 50% reduction in viable tumor. To date, 10 of the 12 responders remain in remission, while the 2 other patients maintained remissions for 200+ days. Median survival time from the date of diagnosis for all patients has not yet been reached and is currently in excess of 15 months.
IOM Report Faults Nation's Record of Medical Mistakes
January 1st 2000WASHINGTON-An Institute of Medicine (IOM) committee has urged instituting a comprehensive strategy to sharply reduce medical errors that result in needless death and injury. According to an IOM report, one study put the annual number of deaths in the United States from medical mistakes at 44,000 and a second study concluded the toll reached 98,000.
Researchers to Assess Garlic and Behavioral Dietary Interventions
January 1st 2000ROCKVILLE, Md—Evidence supporting the use of garlic in cancer prevention and the efficacy of preventive behavioral dietary interventions to reduce cancer risk will be assessed in studies ordered by the Agency for Health Care Policy and Research. The agency assigned the studies to two of its Evidence-based Practice Centers—the Research Triangle Institute and the University of North Carolina at Chapel Hill, and the University of Texas Health Sciences Center, San Antonio.
California Report Documents Dangers Beyond Cancer of Secondhand Smoke
January 1st 2000BETHESDA, Md-A new report from the California state government links secondhand smoke to a number of diseases, including lung and nasal-sinus cancers, heart disease, and sudden infant death syndrome (SIDS). The National Cancer Institute has taken the lead in distributing the 430-page document nationwide.
Celebrex Is Approved for Polyp Reduction in FAP Patients
January 1st 2000BETHESDA, Md-G.D. Searle & Co. has won FDA approval for its COX-2 inhibitor Celebrex (celecoxib) as an oral adjunct to usual care (endoscopic surveillance and surgery) to reduce the number of adenomatous colorectal polyps in patients with familial adenomatous polyposis (FAP). The FDA initially approved Celebrex for treating osteoarthritis and rheumatoid arthritis in April 1998.
HIV+ Lymphoma Patients Safely Undergo Stem Cell Transplant
January 1st 2000NEW ORLEANS-The use of highly active antiretroviral therapy (HAART) in HIV-infected individuals with lymphoma may make it possible for them to receive high-dose chemotherapy with autologous stem cell transplantation (ASCT), according to a study conducted at City of Hope National Medical Center, Los Angeles.
US Smoking Rates No Longer Falling, Due to More Young Smokers
December 1st 1999ATLANTA-Smoking rates among adults in the United States have dropped dramatically over the past 30 years, from 44% in 1965 to 25.5% in 1990, but now the rate seems to have leveled off, the Centers for Disease Control and Prevention (CDC) said in a report.
Americans Favor Higher Cigarette Tax to Balance the Budget
December 1st 1999WASHINGTON-Americans across the political spectrum would prefer that Congress raise the federal excise tax on cigarettes rather than cut funding for existing programs or spend Social Security funds in order to meet federal budget needs, according to a new poll.
Saint Vincents Hospital Opens Comprehensive Cancer Center
December 1st 1999NEW YORK-On October 4, Sister Elizabeth Vermaelen, president of the Sisters of Charity of St. Vincent de Paul of New York, welcomed His Eminence John Cardinal O’Connor, New York Mayor Rudolph Giuliani, and more than 200 other guests to celebrate the grand opening and dedication of The Saint Vincents Comprehensive Cancer Center.
New Breast Biopsy Techniques Allow ‘One-Stop’ Procedures
December 1st 1999TOWSON, Md-New breast biopsy techniques are making it more likely that one-stop procedures will become standard of care for small lesions. With this technique, lesions are sampled and removed for biopsy in a minimally invasive procedure, said Rachel Brem, MD, assistant professor of radiology and oncology at the Johns Hopkins Medical Institutions’ Breast Imaging Center.
Director of NCI Mentioned as a Candidate to Head NIH
December 1st 1999WASHINGTON-National Cancer Institute director Richard D. Klausner, MD, was among the names immediately mentioned as Washington policy wonks and the biomedical community began speculating about who might replace Harold Varmus, MD, as director of the National Institutes of Health.
Challenges in Designing Chemoprevention Trials
December 1st 1999BUFFALO, NY-The 1990s have seen a new focus on cancer prevention, particularly chemoprevention. Researchers must use results of basic, clinical, and translational chemoprevention studies to design more effective trials to further this field, Scott M. Lippman, MD, said at the New Horizons in Cancer Prevention Symposium, hosted by Roswell Park Cancer Institute.
Anesthetic Interventions Rise When Anesthesiologists Join the Pain Team
December 1st 1999HOUSTON--Development of a specialized anesthesiology pain team led to a jump in pain consultations by anesthesiologists and in the number of anesthetic procedures performed for pain control at The University of Texas M.D. Anderson Cancer Center
Worldwide UN Survey Shows Many Impediments to Morphine Availability
December 1st 1999MADISON, Wis-In attempting to increase availability of opiates for pain, "we are really up against the war on drugs," David E. Joranson, MSSW, said, "because it is the same laws aimed at preventing illicit narcotic trafficking that also control medical availability of opioid analgesics, and some governments may be reluctant to relinquish that control."
UnitedHealthcare Plan Gives Physicians Final Say on Care
December 1st 1999MINNEAPOLIS-United-Healthcare, a subsidiary of UnitedHealth Group, has announced that it is further advancing its philosophies on consumer choice and physician autonomy through an initiative called Care Coordination. The new initiative makes obsolete certain programs associated with traditional managed care, such as preauthorization for inpatient hospital procedures.
Radiation Oncology Clinical Research Seminar to be Held at the University of Florida
December 1st 1999A three-day interdisciplinary cancer conference will be held March 2 through 4, 2000, at the Best Western Gateway Grand in Gainesville, Florida. The seminar will emphasize the latest advances in radiation therapy techniques and results. It will include refresher courses by senior faculty, panel discussions, and new departmental research results. Visiting Professor will be Professeur Jean-Pierre Gerard, Service de Radiotherapie-Oncologie, Hôpitaux de Lyon, France. Other presentations will be made by clinicians from the Department of Radiation Oncology,University of Florida.
Withdrawal Syndrome After Stopping Opioids Is Not Evidence of Drug Dependence, WHO Committee Says
December 1st 1999VANCOUVER, BC-Drug dependence is not physical dependence alone, nor is it the same as drug tolerance. "Drug dependence is primarily psychological dependence, or compulsive use of drugs for their mood-altering effects and continued use despite harm," David E. Joranson, MSSW, said at the WHO workshop on cancer pain.
$70 Million Will Fund Tobacco Study Centers at Seven Universities
December 1st 1999BETHESDA, Md-Two components of the National Institutes of Health will spend about $70 million over 5 years to fund Transdisciplinary Tobacco Use Research Centers at seven universities. The first year’s grants from the National Cancer Institute and the National Institute on Drug Abuse (NIDA) will total $14.5 million. In addition, the Robert Wood Johnson Foundation has committed another $14 million over the 5 years.
Cancer Risk of Veterans Exposed to Nuclear Weapons Tests Unresolved
December 1st 1999WASHINGTON-The latest effort to establish whether exposure to radiation during nuclear weapons tests caused leukemia in some military personnel has left the issue largely unresolved. The study by the Institute of Medicine (IOM) found a 14% increase in leukemia deaths among test participants, compared with a control group, but the increase was not significant. The increase was significant, however, for soldiers exposed to land-based testing.
FDA Appeals Court Ruling About Off-Label Drug Materials
December 1st 1999WASHINGTON-A federal appeals court has granted expeditious status to an appeal seeking to overturn a US District Court decision that found parts of the Food and Drug Administration Modernization Act (FDAMA) unconstitutional. The district court ruling restricted the FDA’s powers to regulate the distribution by pharmaceutical companies to physicians of materials regarding off-label uses of drugs. [See Oncology News International, Oct. 1999, page 1.] The US Court of Appeals for the District of Columbia will hear oral arguments in the case on Jan. 4, 2000.
HAART Offers Some HIV Patients Near-Normal Survival
December 1st 1999SAN FRANCISCO-Long-term estimates of survival utilizing data on 4,500 patients suggest that some people with HIV taking HAART (highly active antiviral therapy) may have a near-normal life expectancy. In a session on HIV at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), A.C. Justice, MD, of the Veterans Administration Pittsburgh Healthcare System, presented 2 years of recent data estimating long-term or immediate survival in the post-HAART era.
Solution to Cancer Lies at Molecular Level
December 1st 1999BUFFALO, NY-Cancer encompasses more than 100 different diseases and is caused by a series of molecular changes affecting cellular function. “We will find the solution to cancer at the molecular level. There are common patterns in tumor formation and certain keys that are associated with those patterns,” said Carlo Croce, MD, director of the Kimmel Cancer Center, and professor of microbiology and immunology, Thomas Jefferson University, Philadelphia.